Foghorn Therapeutics Inc. (NASDAQ: FHTX) is a Healthcare company (Biotechnology) with a market capitalization of $110M. The Maz Rating grades it against the other companies in its sector.
Foghorn Therapeutics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.83, Foghorn Therapeutics Inc. trades at 25.4x trailing earnings and 0.9x sales, with an EV/EBITDA of 6.5. Over the last twelve months it generated about $116M of revenue and $4M of net income. It runs a gross margin of 99.1%, an operating margin of 5.9% and a net margin of 8.4%. It shows return on equity of -14.2%, return on invested capital of 4.2% and a free cash flow yield of -78.2%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 4.24. Over the past 52 weeks the share price ranged from $1.73 to $7.61, with a beta of 3.21.
Foghorn Therapeutics Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 8 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Foghorn Therapeutics Inc. (FHTX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 63.0% / 30% · Interest income / Revenue 1.83% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 63.0% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 1.83% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 63.0% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 1.83% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.23% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 82.0% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 1.83% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 81.8% / 33.33% · (Cash+Recv) / Total Assets 81.8% / 33.33% · Interest income / Revenue 1.83% / 5% | Fail |
No. As of September 2026, Foghorn Therapeutics Inc. (FHTX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Foghorn Therapeutics Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
About 1.83% of each dividend: Foghorn Therapeutics Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.